Manganoporphyrin-lonidamine combined drug for treating tumor

A technology of manganese porphyrin and medicine, which is applied in the field of combined medicine to achieve the effect of enhancing curative effect and reducing toxic and side effects

Inactive Publication Date: 2011-04-06
BEIJING LUZHU BIOTECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the combination of manganese

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Manganoporphyrin-lonidamine combined drug for treating tumor
  • Manganoporphyrin-lonidamine combined drug for treating tumor
  • Manganoporphyrin-lonidamine combined drug for treating tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1 manganese porphyrin carmustine compound injection

[0031] The formula is as follows:

[0032] Manganese Porphyrin 400mg

[0033] Carmustine 3.5g

[0034] Polyethylene glycol 150ml

[0035] Add water for injection to 250ml

[0036]

[0037] Makes 50

[0038] Preparation Process:

[0039] Vials and rubber stoppers should be roughly washed first, and then finely washed with water for injection filtered through a 0.45 μm microporous membrane until foreign matter is visible, and then dried for later use.

[0040] Add the prescribed amount of manganese porphyrin and 50ml of polyethylene glycol into the dosing tank, and dissolve it completely as solution 1.

[0041] Add the prescribed amount of carmustine and 100ml of polyethylene glycol to another dosing tank to completely dissolve it as solution 2.

[0042] Combine solutions 2 and add them to solution 1, heat at 80°C for 10 minutes, add water for injection to the full amount ...

Embodiment 2

[0043] Example 2 Evaluation of the therapeutic effect of manganese porphyrin and sodium cromoglycate in combination with pancreatic cancer in mice

[0044] Human pancreatic cancer MIAPaCa-2 cell suspension was adjusted to 5×10 per ml 6 cells, 0.2ml cell suspension (containing 1×10 6 cells) were inoculated in the pancreas of 30 immune complex deficient female mice, and were randomly divided into three groups after 1 week. The control group (NS) injected normal saline 0.2ml into the tail vein every day, and the sodium cromolyn group injected sodium cromolyn 30mg / day into the tail vein every day. kg body weight, manganese porphyrin+cromoglycate sodium group was injected with manganese porphyrin 2mg / kg body weight and cromolyn sodium 30mg / kg body weight every day. After continuous injection for 3 weeks, the animals were sacrificed, the tumor was dissected and extracted, and the tumor volume was measured (V=1 / 6×π×length×height×width). Tumor tissues were fixed in paraformaldehyde ...

Embodiment 3

[0055] Therapeutic evaluation of embodiment 3 manganese porphyrin and sodium dichloroacetate combined drug on rat lung cancer

[0056] Human lung cancer A549 cell suspension was adjusted to 15×10 per ml 6 cells, take 0.2ml (3×10 6 3 cells) in the left forelimb axillary subcutaneous injection in 30 male adult nude rats, two weeks after the inoculation, they were randomly divided into three groups, the control group (NS) injected normal saline 0.2ml into the tail vein every day, and the sodium dichloroacetate group injected dichloroacetate Sodium acetate is dissolved in feeding water with 0.075g / L, free intake every day), manganese porphyrin+sodium dichloroacetate group is except giving the feeding water containing sodium dichloroacetate, and tail vein injects manganese porphyrin 2mg every day / kg body weight. Measure the maximum diameter of the tumors of animals in each group with a vernier caliper every week until four weeks after the administration, and then kill the nude r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a manganoporphyrin-lonidamine combined drug for treating tumor, comprising manganoporphyrin, lonidamine and one or more optional pharmacy-acceptable vectors. The inventor of the application carries out a series of experimental researches. Proved by the experiment, after manganoporphyrin without a tumor-resistant function is combined with the lonidamine for pharmacy, the treatment effect for the tumor can be remarkably improved, the toxicity of the medicine can be reduced, the survival time of animals can be prolonged and the unexpected effects can be obtained.

Description

technical field [0001] The present invention relates to a combined drug for treating tumors, in particular to a combined drug containing manganese porphyrin for treating tumors. Background technique [0002] In recent years, there are 1.6-1.7 million new cancer patients in my country every year, and the total number is about 4.5 million. Both its morbidity and mortality are on the rise. According to the "Summary of China's Health Statistics in 2009" released by the Ministry of Health, among the top ten disease-related death rates in some cities and counties in 2008, malignant tumors ranked first, and they have become the number one killer that endangers human health. [0003] Although many antineoplastic drugs exist, and more compounds have been found to have antineoplastic effects, such as dichloroacetate and cromolyn sodium. However, due to the lack of ideal selectivity, most anti-tumor drugs have inhibitory or damaging effects on normal human tissue cells while inhibiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/416A61K31/409A61P35/00
Inventor 厉保秋
Owner BEIJING LUZHU BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap